AI agent runs brain injection on a live mouse
A biotech startup let an AI agent control a robotic rig to inject a gene therapy into a mouse's brain, with humans approving the plan and a vet doing the first surgery.
The facts
- According to Wired, Exin Therapeutics CEO Gabriel Ocana Santero's team connected an AI agent to a custom rig to inject a gene therapy into a mouse with epilepsy, testing whether it reduces seizures.
- The agent picked the therapy from 19 options, plus the brain region and injection coordinates. A veterinary surgeon did the craniotomy first, and a human had to approve the plan.
- The team says Claude Opus 5.5 refused to guide the needle, so they switched to Claude Sonnet 5. A coordinate glitch then forced a separate Opus 5 agent to fix the code, and the procedure ran slightly over an hour instead of about 45 minutes.
- The team is waiting for the therapy to take effect before assessing its impact on seizures. Anthropic did not respond to Wired's request for comment.
Case notes · Danny's take
Why it matters
Most AI news is about chatbots writing text. This is an agent with a needle, a camera and a live animal. The two moments that stand out are the model refusing the injection and later refusing to edit its own code. That's not a bug. That's a guardrail doing its job, in the wrong place at the wrong time. The harder question is who is accountable when an agent can act in the physical world.
For builders
Agents wired into physical equipment need hard limits: human approval of plans, a kill switch, and locked code. The team's workaround, a second agent that was not told a live surgery was under way, is the part to scrutinise. Design for the case where your safeguards slow things down.
Not financial advice. Do your own investigation.
This story was summarised with AI from Wired's reporting and checked against our editorial policy. Danny's take reflects his views. Disclaimer.
Danny Walter
Founder of Moon Republic, Volt Terminal and Moon Republic Academy. Author of The Market Is a Crime Scene and After the Applause.